NewHold Investment Corp. III

# Signal Note: Driehaus Capital enters NHICW Driehaus Capital's $3.9M initiation in NewHold Investment Corp. III (a SPAC) signals conviction in an upcoming biotech merger target, though the specific asset remains undisclosed until formal announcement. As a growth-focused manager with meaningful biotech exposure, this position sizing suggests the target addresses a substantial market opportunity or has differentiated clinical data approaching inflection points. Monitor SEC filings for the merger announcement to assess clinical stage, indication focus, and near-term catalysts (trial readouts, regulatory milestones).